

OCT 27 2004

HEDMAN & COSTIGAN, P.C.
ATTORNEYS AT LAW

1185 AVENUE OF THE AMERICAS
NEW YORK, NEW YORK 10036-2648

JAMES V. COSTIGAN
KENNETH F. FLOREK
ALAN B. CLEMENT
MARTIN P. ENDRES
KATHLEEN A. COSTIGAN
JOHN F. VOLPE
KATHARINE G. LOVING
NICHOLAS P. CHIARA
PETER J. FALLON

EDWARD A. HEDMAN
1927-2004

TELEPHONE
(212) 302-8989

TELECOPIER
(212) 302-8988

E-MAIL
mail@hgcpatent.com

URL: <http://www.hgcpatent.com>

TELECOPIER TRANSMISSION

TO: Examiner David J. Steadman FAX NO.: (703) 872-9306

FROM: James V. Costigan

TOTAL NO. OF PAGES INCLUDING THIS COVER SHEET: 3

DATE: October 27, 2004 CHARGE: 515-4218

RE: Serial No. 09/815,533

(IF THERE ARE ANY PROBLEMS REGARDING THIS TRANSMISSION,
PLEASE CALL (212) 302-8989, EXT. 40 OR 41)

CONFIDENTIAL

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY BE SUBJECT
TO THE ATTORNEY-CLIENT PRIVILEGE OR ATTORNEY WORK PRODUCT EXCLUSION.


THIS FACSIMILE IS ONLY INTENDED FOR THE DESIGNATED RECIPIENT(S). ANY RECIPIENT OTHER
THAN THE DESIGNATED RECIPIENT(S) IS HEREBY NOTIFIED THAT ANY DISCLOSURE OR USE OF THE
INFORMATION IS UNAUTHORIZED AND PROHIBITIVE. IF YOU HAVE RECEIVED THIS FACSIMILE IN
ERROR, PLEASE NOTIFY: HEDMAN & COSTIGAN, P.C. BY TELEPHONE AT (212) 302-8989

REMARKS: ☒ Urgent ☒ For Your Review/Comments ☐ Reply ASAP ☐ FYI
☐ Per Your Request Original ☐ will / ☐ will not follow

Attached is a Draft Amendment

Certificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to the United
States Patent & Trademark Office, Fax No. (703) 872-9306 on October 27, 2004.


Glenda Carrasquillo

**RECEIVED
CENTRAL FAX CENTER****OCT 27 2004**Docket No.: 515-4218IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT OPERATIONS

In re Application of:)
)
 Achille Arini et al.) Group Art Unit: 1652
)
) Examiner: Steadman, David J.
Serial No.: 09/815,533)
)
Filed: March 16, 2001)
)

For: METHOD FOR THE PRODUCTION OF PHARMACEUTICALLY ACTIVE
RECOMBINANT PROTEINS

DRAFT CLAIMS

93. (new) A process for the production of recombinant two chain urokinase (tc-uPA) into the culture medium of an eukaryotic cell line wherein at least 95% of the total urokinase is catalitically active two chain urokinase (tc-uPA), said process comprising the following steps:

- a) culturing a mammalian cell line which has been genetically manipulated with a cDNA sequence encoding for a urokinase precursor in a culture media comprising an alkanoic acid selected from the group consisting of: butyric acid, sodium butyrate sodium propionate, magnesium butyrate, tributyrin and phenyl-butyrate, their derivatives or salts thereof,
- b) continuing said culture for a time of at least 120 hours.

94. A process according to claim 93 further comprising the recovery of the cell culture supernatant for the isolation of recombinant human tc-uPA.

95. A process according to claim 93 wherein said eukaryotic cell line is selected from CHO and CHO-Messi.

96. A process according to claim 93 wherein said cell culture medium is serum-free.

97. A process according to claim 93 wherein the concentration of said alkanolic acids is from 0.1 to 20 mM.

98. A process according to claim 93 wherein after said alkanolic acids are added, the cell culture is continued at a temperature from 30°C to 37°C.

99. A process according to claim 98 wherein said temperature is from 33°C to 35°C.

100. A process according to claim 94 wherein the tc-uPA in said cell culture medium is at least 4000iU/ml.

101. A process according to claim 94 wherein, the recovered culture medium is acidified with a weak acid to pH from 5.0 to 5.8, optionally a non-ionic detergent is added and the culture medium is then filtered.